MAUREL, Marine, Jennifer HOWARD, Esther KISSLING, Francisco POZO and Petr HUSA. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. EUROSURVEILLANCE. SWEDEN: EUR CENTRE DIS PREVENTION & CONTROL, 2024, vol. 29, No 8, p. 1-8. ISSN 1025-496X. Available from: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089. |
Other formats:
BibTeX
LaTeX
RIS
@article{2378957, author = {Maurel, Marine and Howard, Jennifer and Kissling, Esther and Pozo, Francisco and Husa, Petr}, article_location = {SWEDEN}, article_number = {8}, doi = {http://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089}, keywords = {Influenza A vaccine effectiveness; European primary care; hospital multicentre studies}, language = {eng}, issn = {1025-496X}, journal = {EUROSURVEILLANCE}, title = {Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024}, url = {https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.8.2400089}, volume = {29}, year = {2024} }
TY - JOUR ID - 2378957 AU - Maurel, Marine - Howard, Jennifer - Kissling, Esther - Pozo, Francisco - Husa, Petr PY - 2024 TI - Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024 JF - EUROSURVEILLANCE VL - 29 IS - 8 SP - 1-8 EP - 1-8 PB - EUR CENTRE DIS PREVENTION & CONTROL SN - 1025496X KW - Influenza A vaccine effectiveness KW - European primary care KW - hospital multicentre studies UR - https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.8.2400089 N2 - Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively. ER -
MAUREL, Marine, Jennifer HOWARD, Esther KISSLING, Francisco POZO and Petr HUSA. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. \textit{EUROSURVEILLANCE}. SWEDEN: EUR CENTRE DIS PREVENTION \&{} CONTROL, 2024, vol.~29, No~8, p.~1-8. ISSN~1025-496X. Available from: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089.
|